SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

Pharmacotherapy

Volumn 37, Issue 2, 2017, Pages 187-194

  Burke, Kelly R ^a   Schumacher, Christine A ^a   Harpe, Spencer E ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

adverse drug reactions; diabetes; Food and Drug Administration; ketoacidosis; sodium glucose cotransporter 2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCOSE; INSULIN; IPRAGLIFLOZIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

ABDOMINAL PAIN; ARTICLE; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LATENT AUTOIMMUNE DIABETES IN ADULTS; MAJOR SURGERY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT HISTORY OF SURGERY; SYSTEMATIC REVIEW; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85013025315     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1881     Document Type: Article

References (33)

1. American Diabetes Association: standards of medical care in diabetes—2016. Diabetes Care 2016;39(Suppl 1):S1–110.
2. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2016 executive summary. Endocr Pract 2016;22:84–113.
3. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849–52.
4. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38(12):2258–65.
5. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind placebo-controlled pilot study. Diabetes Care 2015;38(3):412–9.
6. Mosley JF, Smith L, Everton E, Fellner C. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T 2015;40(7):451–62.
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
8. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, 15 May 2015. Available from http://www.fda.gov/downloads/DrugSafety/UCM446954.pdf. Accessed September 15, 2015.
9. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680–6.
10. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687–93.
11. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections, 2015. Available from http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed March 15, 2016.
12. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016;22(6):753–62.
13. Bonanni FB, Fei P, Fitzpatrick LL. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. Surg Obes Relat Dis 2016;2:e11–2.
14. Burr K, Nguyen AT, Rasouli N. A case report of ketoacidosis associated with canagliflozin (Invokana). Poster presented at ENDO 2015, March 7, 2015, San Diego, CA. Available from https://endo.confex.com/endo/2015endo/webprogram/COP.html. Accessed March 7, 2016.
15. Chaudry F, Stacpoole P. Diabetic ketoacidosis following SGLT2 inhibitor therapy in DM2. Poster presented at AACE 2015, May 15, 2015, Nashville, TN. Available from http://am2015.aace.com/sites/all/files/2015-Final-Abstract.pdf. Accessed March 21, 2016.
16. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Invest 2015;6:587–90.
17. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycemic diabetic ketoacidosis. Lancet 2015;3:503–4.
18. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep 2015;2015:150042.
19. Kelwade J, Sethi BK, Nagesh SV, Vaseem A. A case of “pseudo-ketoacidosis.” Indian J Endocrinol Metab 2014;18(5):743.
20. Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care 2016;39:e3.
21. Srivali N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Acute pancreatitis in the use of canagliflozin: a rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharm 2015;6(3):101–2.
22. St. Hilaire R, Costello H. Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication. Am J Emerg Med 2015;33:604.e3–4.
23. Storgaard H, Bagger JI, Knop FK, Vilsboll T, Rungby J. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol 2016;118:168–70.
24. Venkatesh B, Moore G, Gill D, Kelly W. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases. Crit Care Resusc 2015;17(4):280–2.
25. Umpierrez G, Korytkowski M. Diabetic emergencies—ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 2016;12(4):222–32.
26. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638–42.
27. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care 2016;39:1115–22.
28. Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR, Aguilar RB. The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care 2016;39(2):179–86.
29. Ostergaard JA, Laugesen E, Leslie RD. Should there be concern about autoimmune diabetes in adults? Current evidence and controversies. Curr Diab Rep 2016;16(9):82.
30. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006;29(5):970–5.
31. Bell DSH, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am J Ther 2004;11(4):308–11.
32. Campbell RK. Etiology and effect on outcome of hyperglycemia in hospitalized patients. Am J Health Syst Pharm 2010;26(3):589–98.
33. Desborough JP. The stress response to trauma and surgery. Br J Anaesth 2000;85(1):109–17.